0LB2.LSE Supernus Pharmaceuticals, Inc.
- Market cap
- -
- P/E
- 32.5x
- P/B
- -
- ROE
- -5.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0LB2.LSE undervalued?
Graham numberThe Graham number of Supernus Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Supernus Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for Supernus Pharmaceuticals, Inc. yet.
Supernus Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product …
Full company profileSupernus Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Supernus Pharmaceuticals, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 215M | 302M | 409M | 393M | 520M | 580M | 667M | 608M | 662M | 719M | 871M |
| Gross Profit | 203M | 287M | 394M | 376M | 448M | 472M | 494M | 439M | 503M | 644M | 659M |
| Operating Income | 54.2M | 99.5M | 144M | 149M | 184M | 101M | 45.6M | 13.4M | 61.4M | -37.2M | 4.85M |
| EBITDA | 56.6M | 108M | 152M | 180M | 212M | 129M | 153M | 90.0M | 178M | 54.4M | 106M |
| Net Income | 91.2M | 57.3M | 111M | 113M | 127M | 53.4M | 60.7M | 1.32M | 73.9M | -38.6M | -53.0M |
| EPS | 1.76 | 1.07 | 2.05 | 2.10 | 2.36 | 0.98 | 0.98 | 0.02 | 1.32 | -0.68 | -0.89 |
| Balance Sheet | |||||||||||
| Total Assets | 310M | 439M | 1.01B | 1.20B | 1.59B | 1.83B | 1.84B | 1.41B | 1.50B | 1.45B | 1.40B |
| Total Liabilities | 118M | 172M | 556M | 602M | 842M | 1.02B | 951M | 487M | 465M | 391M | 335M |
| Shareholders' Equity | 192M | 267M | 453M | 595M | 745M | 816M | 886M | 922M | 1.04B | 1.06B | 1.06B |
| Cash & Short-term Investments | 90.1M | 140M | 356M | 347M | 423M | 340M | 461M | 255M | 454M | 309M | 359M |
| Total Debt | 34.6M | 26.5M | 354M | 401M | 431M | 427M | 445M | 41.5M | 34.3M | 41.0M | 36.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 66.8M | 115M | 129M | 143M | 138M | 127M | 117M | 111M | 172M | 47.3M | 91.1M |
| Capital Expenditure | 20.4M | 13.2M | 1.65M | 2.74M | 3.69M | 2.05M | 412K | 551K | 725K | 1.34M | 1.06M |
| Free Cash Flow | 46.4M | 101M | 127M | 140M | 135M | 125M | 116M | 111M | 171M | 46.0M | 90.0M |
| Ratios | |||||||||||
| ROE | 47.6% | 21.4% | 24.5% | 19.0% | 17.0% | 6.5% | 6.9% | 0.1% | 7.1% | -3.6% | -5.0% |
| ROA | 29.5% | 13.0% | 11.0% | 9.4% | 8.0% | 2.9% | 3.3% | 0.1% | 4.9% | -2.7% | -3.8% |
| Net Profit Margin | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% | -6.1% |
| Debt to Equity | 0.18x | 0.10x | 0.78x | 0.67x | 0.58x | 0.52x | 0.50x | 0.05x | 0.03x | 0.04x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Supernus Pharmaceuticals, Inc. dividends
Supernus Pharmaceuticals, Inc. has not paid dividends in the last 9 fiscal years.
Who owns Supernus Pharmaceuticals, Inc.
- Insiders 4.32%
- Institutions 95.68%
- Public & others 0.00%
- Free float 51.9M
Supernus Pharmaceuticals, Inc. company profile
- Company name
- Supernus Pharmaceuticals, Inc.
- Ticker
- 0LB2.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 778
- Fiscal year end
- December
- Address
- 9715 Key West Avenue, Rockville, MD, United States, 20850
- Phone
- 301 838 2500
- Website
- supernus.com
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Supernus Pharmaceuticals, Inc. management
9- Mr. Jack A. Khattar M.B.A.Founder, President, CEO, Secretary & Director · born 1961
- Mr. Timothy C. DecSenior VP & CFO · born 1959
- Dr. Padmanabh P. Bhatt Ph.D.Chief Scientific Officer & Senior VP of Intellectual Property · born 1957
- Mr. Frank MottolaSenior VP & Chief Technology Operations Officer · born 1972
- Dr. Jonathan Rubin M.B.A., M.D.Senior VP of Research & Development and Chief Medical Officer · born 1961
- Mr. Taylor RaifordSenior Vice President of Sales
- Dr. William Todd Horich M.B.A., Ph.D.Senior VP & Chief Commercial Officer · born 1973
- Dr. Bryan A. Roecklein Ph.D.Senior VP & Chief Business Officer · born 1959
- Mr. Jeff BozickSenior Vice President of Supply Chain